EICHOR
● Active Not Recruiting
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
Condition: Early Breast Cancer · Sponsor: Novartis Pharmaceuticals
About this study
A phase III, multicenter, randomized, open-label trial to evaluate the efficacy and safety of ribociclib with Endocrine Therapy (ET) as an adjuvant treatment in women and men with Hormone Receptor positive (HR+), Human Epidermal Growth Factor Receptor 2 negative (HER2-) Early Breast Cancer (EBC).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (387)
| University of Alabama at Birmingham-Kirklin Clinic | Birmingham, Alabama, United States | — |
| Cancer Treatment Centers of America | Goodyear, Arizona, United States | — |
| St Bernards Medical Center | Jonesboro, Arkansas, United States | — |
| Comprehensive Blood and Cancer | Bakersfield, California, United States | — |
| UCLA Beverly Hills | Beverly Hills, California, United States | — |
| UCLA Burbank | Burbank, California, United States | — |
| Encino Research Center | Encino, California, United States | — |
| St. Jude Heritage Medical Group | Fullerton, California, United States | — |
| UCLA Hematology Oncology | Laguna Hills, California, United States | — |
| Southern CA Oncology Rsrch Alliance | Los Angeles, California, United States | — |
| Stanford University Medical Center | Palo Alto, California, United States | — |
| UCLA Pasadena HC Hemato Onco | Pasadena, California, United States | — |
+ 375 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03701334